Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), effective from May 1, 2026.

This personnel change marks a significant strategic deployment in the company's financial management team. Dennis Mulroy will succeed the current Chief Financial Officer, taking full responsibility for the company’s financial planning, capital management, investor relations, and compliance disclosures. According to publicly disclosed SEC filings, this executive appointment has been approved by the company’s board of directors. As a biopharmaceutical company focused on messenger RNA (mRNA) therapies and vaccine development, Arcturus Therapeutics has introduced a new CFO to further strengthen its financial structure and provide solid financial support for subsequent R&D progress and commercial expansion.